Cancer Drug Accelerated Approval Could Be Based On Pediatric Studies
Executive Summary
Pharmaceutical companies could gain accelerated approval for oncologic agents based solely on pediatric testing of those drugs, FDA Oncologic Drug Products Division Director Richard Pazdur, MD, suggested
You may also be interested in...
Pediatric Oncology Trials Should Start After Adult Phase I Data – Subcmte.
Pediatric oncology trials usually should be initiated after collection of data from Phase I adult trials, FDA's Pediatric Subcommittee of the Oncologic Drugs Advisory Committee recommended Oct. 17
Pediatric Oncology Subcmte. Should Discuss Timing Of Studies – Workshop
The Pediatric Oncology Subcommittee should determine when it is appropriate to initiate clinical testing of oncologic agents in children, participants at an FDA workshop on pediatric oncology drug development agreed
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011